CRO Orders in Full Recovery, Lab Monkey Supply-Demand Gap Widens
Taylor Wilson
China's CRO sector is posting new-order growth above 30% across the board, yet the annual supply gap for lab monkeys is set to widen to 15,000–20,000 animals — making primate sourcing the decisive variable in earnings divergence.
Why are lab monkeys suddenly so scarce?
Total market demand for lab monkeys in 2026 is projected to exceed 60,000, well above current output — leaving an annual shortfall of roughly 10,000.
Brokerages estimate the gap will widen to 15,000–20,000 per year between 2026 and 2028.
This means → the problem is no longer price but availability. One biopharma R&D head put it bluntly: "It's not just that monkeys are expensive — we can't get them at all."
What went wrong on the supply side?
Cynomolgus macaques — the species most widely used in drug-safety evaluation — take six to seven years from weaning to lab-ready age. Females reach sexual maturity at four and produce just one offspring a year, giving the species almost no production elasticity.
During the last price boom, many breeding farms sold prime-age breeding stock as commercial animals. The result: an ageing population of mother monkeys and declining fertility rates today.
In plain terms = the supply side is paying off old debts — farms cashed in on breeding stock years ago, and now need six to seven years to rebuild the herd.
What is driving demand higher?
According to the NMPA's *2025 Annual Report on Clinical Trial Progress*, total clinical trials in China topped 5,000 for the first time, a record high.
R&D in complex biologics — multi-specific antibodies, ADCs (antibody–drug conjugates, which attach a chemotherapy payload to a targeting antibody), peptides, small nucleic acids, and cell & gene therapies — continues to accelerate.
This means → these drug types depend on non-human primate models in preclinical evaluation far more than traditional small molecules do, amplifying rigid demand for lab monkeys.
How is monkey sourcing reshaping competition among CROs?
CROs with captive breeding farms or stable supply get scheduling power and pricing leverage; those reliant on external procurement face cost and margin pressure.
Joinn Biologics (06127) holds more than 50,000 cynomolgus macaques in-house, 90% captive-bred — the earliest and largest primate reserve among China's safety-assessment CROs.
The company guides H1 2026 net profit at RMB 600–900 million, up roughly 885%–1,377% year-on-year, driven mainly by fair-value gains on biological assets as monkey prices rose.
In plain terms = Joinn's monkey colony is effectively a "mine on the balance sheet" — when monkey prices rise, book profits rise with them.
How strong is the order recovery across the CRO sector?
WuXi AppTec (02359): Q1 backlog up 23.6% YoY; continuing-operations revenue up 39.4%; adjusted net profit up 71.7%.
Pharmaron (03759): H1 new orders up over 30% YoY; small-molecule CDMO new orders up over 50%.
Joinn Biologics: quarterly new-order growth since Q3 2025 ran at +24%, +118%, +112%; Q1 bookings hit RMB 910 million (+111.6% YoY); backlog stood at roughly RMB 3.1 billion.
WuXi Biologics (02269): 2025 revenue of RMB 21.79 billion (+16.7% YoY); 209 new projects signed, a record; 945 projects in hand including 74 Phase III and 25 commercial-manufacturing mandates.
How long can this divergence last?
Huafu Securities notes that preclinical CRO new-order growth surged to roughly 40% in 2025. As earlier low-priced orders roll off, strong new bookings should translate into a clear revenue-and-profit inflection for the sector in 2026.
WuXi AppTec guides 2026 full-year continuing-operations revenue growth of 18%–22%, targeting total revenue of RMB 51.3–53.0 billion.
This reflects a sector shifting from the "order confirmation" phase to the "profit delivery" phase — but two things must be verified: whether the monkey supply gap widens as projected, and whether CROs without captive primate sources can pass cost pressure through to downstream clients.
Content is for reference only, not financial advice.